行情

EARS

EARS

Auris Medical Holding Ltd
NASDAQ

实时行情|Nasdaq Last Sale

0.8100
-0.0099
-1.21%
已收盘, 16:07 03/30 EDT
开盘
0.8191
昨收
0.8199
最高
0.8401
最低
0.7615
成交量
2.43万
成交额
--
52周最高
7.00
52周最低
0.6500
市值
1,950.27万
市盈率(TTM)
-0.1157
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测EARS价格均价为14.77,最高价位14.77,最低价为14.77。

EPS

EARS 新闻

更多
  • 房多多2019年第四季度收入破10亿元 同比增长50%
  • 新浪财经 · 1小时前
  • 房多多2019年全年收入36亿元 GMV同比增长85.1% 高于市场预期
  • 新浪财经 · 1小时前
  • 瑞银:随着库存增加 布伦特和WTI原油价格必将跌破20美元
  • 新浪财经 · 1小时前
  • 印尼央行行长Warjiyo称东盟的央行开会讨论刺激措施
  • 新浪财经 · 1小时前

所属板块

生物技术和医学研究
+4.00%
制药与医学研究
+4.75%

热门股票

代码
价格
涨跌幅

EARS 简况

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.
展开

微牛提供Auris Medical Holding Ltd(NASDAQ-EARS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的EARS股票新闻,以帮助您做出投资决策。